BioSpace News Archive

AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2023.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended June 30, 2023.

Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels.

Telavant, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to help patients living with inflammatory and fibrotic diseases, announced today the initiation of the TAHOE study, a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active CD, with first patient dosed.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023.

Avenue Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.

Wave Life Sciences Ltd. will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 3, 2023, to review the company’s second quarter 2023 financial results and provide business updates.

Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2023.